Rosalia Caballero

Breastfeeding shapes a unique tumor-immune landscape in pregnancy-associated breast cancer from GEICAM-EMBARCAM study.

Journal: Breast cancer research : BCR

Published: March 19, 2026

Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 10, 2026

Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 15, 2026

Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor-Positive Breast Cancer in the GEICAM/9906 Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 15, 2026

Correction: Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: November 25, 2025

Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial.

Journal: JCO precision oncology

Published: July 09, 2025

Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2- Highly Proliferative Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 30, 2025

Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 30, 2025

FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 27, 2025

Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study.

Journal: NPJ breast cancer

Published: August 06, 2024

Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: October 27, 2023

Gestational breast cancer: distinctive molecular and clinico-epidemiological features.

Journal: Journal of mammary gland biology and neoplasia

Published: October 27, 2023

Breastfeeding shapes a unique tumor-immune landscape in pregnancy-associated breast cancer from GEICAM-EMBARCAM study.

Breastfeeding shapes a unique tumor-immune landscape in pregnancy-associated breast cancer from GEICAM-EMBARCAM study.

Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trial.

Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trial.

Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial.

Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial.

Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor-Positive Breast Cancer in the GEICAM/9906 Trial.

Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor-Positive Breast Cancer in the GEICAM/9906 Trial.

Correction: Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.

Correction: Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.

Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial.

Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial.

Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2- Highly Proliferative Breast Cancer.

Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2- Highly Proliferative Breast Cancer.

Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer.

Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer.

FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial.

FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial.

Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study.

Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study.

Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.

Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.

Gestational breast cancer: distinctive molecular and clinico-epidemiological features.

Gestational breast cancer: distinctive molecular and clinico-epidemiological features.

Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trial.

Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trial.